FRE N Stock Overview
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Fresenius SE & Co. KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €487.49 |
| 52 Week High | €533.82 |
| 52 Week Low | €450.63 |
| Beta | 1.05 |
| 1 Month Change | 8.18% |
| 3 Month Change | n/a |
| 1 Year Change | -10.77% |
| 3 Year Change | -49.24% |
| 5 Year Change | -55.50% |
| Change since IPO | -69.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| FRE N | MX Healthcare | MX Market | |
|---|---|---|---|
| 7D | 0% | 8.5% | 1.0% |
| 1Y | -10.8% | 2.3% | 2.4% |
Return vs Industry: FRE N underperformed the MX Healthcare industry which returned 2.3% over the past year.
Return vs Market: FRE N underperformed the MX Market which returned 2.4% over the past year.
Price Volatility
| FRE N volatility | |
|---|---|
| FRE N Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 5.4% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in MX Market | 6.0% |
| 10% least volatile stocks in MX Market | 2.1% |
Stable Share Price: FRE N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine FRE N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1912 | 193,865 | Michael Sen | www.fresenius.com |
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
Fresenius SE & Co. KGaA Fundamentals Summary
| FRE N fundamental statistics | |
|---|---|
| Market cap | Mex$285.19b |
| Earnings (TTM) | Mex$5.64b |
| Revenue (TTM) | Mex$405.67b |
50.6x
P/E Ratio0.7x
P/S RatioIs FRE N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FRE N income statement (TTM) | |
|---|---|
| Revenue | €22.46b |
| Cost of Revenue | €17.35b |
| Gross Profit | €5.11b |
| Other Expenses | €4.79b |
| Earnings | €312.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 31, 2024
| Earnings per share (EPS) | 0.55 |
| Gross Margin | 22.74% |
| Net Profit Margin | 1.39% |
| Debt/Equity Ratio | 62.2% |
How did FRE N perform over the long term?
See historical performance and comparison